ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS
SEOUL,South Korea,Jan. 14,2025-- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for \'Pemziviptadil (development code name PF1804),\' a treatment for DMD (Duch